BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kollàr A, Maruzzo M, Messiou C, Cartwright E, Miah A, Martin-Liberal J, Thway K, McGrath E, Dunlop A, Khabra K, Seddon B, Dileo P, Linch M, Judson I, Benson C. Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program. Clin Sarcoma Res 2014;4:17. [PMID: 25905001 DOI: 10.1186/2045-3329-4-17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Z, Jiang T, Wang W, Piao D. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis. Medicine (Baltimore) 2017;96:e8698. [PMID: 29310342 DOI: 10.1097/MD.0000000000008698] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
2 Ivanyi P, Eggers H, Hornig M, Kasper B, Heissner K, Kopp HG, Kirstein M, Ganser A, Grünwald V. Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors. Mol Clin Oncol 2020;13:72. [PMID: 33005406 DOI: 10.3892/mco.2020.2143] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Szucs Z, Jones RL. Perspectives on the evolving state of the art management of gastrointestinal stromal tumours. Transl Gastroenterol Hepatol 2018;3:21. [PMID: 29780899 DOI: 10.21037/tgh.2018.04.02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Brzozowska M, Wierzba W, Szafraniec-Buryło S, Czech M, Połowinczak-Przybyłek J, Potemski P, Śliwczyński A. Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland. Med Sci Monit 2019;25:3846-53. [PMID: 31121600 DOI: 10.12659/MSM.914517] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
5 Smrke A, Gennatas S, Huang P, Jones RL. Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. Future Oncol 2020;16:1639-46. [PMID: 32517495 DOI: 10.2217/fon-2020-0348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, van der Graaf WT, Jones RL. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017;13:93-107. [PMID: 27600498 DOI: 10.2217/fon-2016-0192] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 7.8] [Reference Citation Analysis]
7 Hu CH, Yeh CN, Chen JS, Tsai CY, Wang SY, Cheng CT, Yeh TS. Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non-randomized, single-center study. Oncol Lett 2020;20:2131-42. [PMID: 32782530 DOI: 10.3892/ol.2020.11756] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Zhao B, Zhao H. Incidence and risk of regorafenib-induced hepatotoxicity. Oncotarget 2017;8:84102-11. [PMID: 29137408 DOI: 10.18632/oncotarget.21106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ronellenfitsch U, Henzler T, Menge F, Dimitrakopoulou-Strauss A, Hohenberger P. [Advanced gastrointestinal stromal tumors : What role does surgery currently play in multimodal concepts?]. Chirurg 2016;87:389-97. [PMID: 27080051 DOI: 10.1007/s00104-016-0180-7] [Reference Citation Analysis]